MedTrace Logo

MR Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence

NCT04217018 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2021-02-08

No results posted yet for this study

Summary

This registry aims to collect clinical, molecular and radiologic data including detailed clinical parameters, molecular pathology (1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations, etc) and conventional/advanced/new MR sequences (T1, T1c, T2, FLAIR, ADC, DTI, PWI, etc) of patients with primary gliomas. By leveraging artificial intelligence, this registry will seek to construct and refine algorithms that able to predict molecular pathology or subgroups of gliomas.

Conditions

Interventions

DIAGNOSTIC_TEST

Prediction of molecular pathology

Prediction of 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations or molecular subgroups by leveraging AI

Sponsors & Collaborators

  • Sun Yat-sen University

    collaborator OTHER

  • The First Affiliated Hospital of Zhengzhou University

    lead OTHER

Eligibility

Min Age
1 Year
Max Age
95 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2027-01-01
Completion
2027-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04217018 on ClinicalTrials.gov